This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Idera Announces Presentation On Preclinical Studies Of TLR Antagonist Candidate In Models Of Atherosclerosis At American Heart Association Scientific Sessions 2011

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the presentation of preclinical data indicating that its dual antagonist of Toll-like receptor (TLR) 7 and TLR9 reduced restenosis and atherosclerosis in a mouse model of hypercholesterolemia. The studies were conducted in collaboration with Professor Paul Quax, Ph.D., from the Department of Surgery, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, the Netherlands. The oral presentation, entitled “TLR7/9 activation enhances neointima formation in hypercholesterolemic APOE*3Leiden mice,” was made at the American Heart Association (AHA) Scientific Sessions 2011 held in Orlando, FL.

“There is a growing body of evidence that inflammation plays a significant role in cardiac diseases and antagonism of TLRs may interrupt these inflammatory processes,” commented Professor Quax. “By inhibiting TLR7 and TLR9, we were able to reduce inflammation and limit vascular remodeling in a preclinical model. These new preclinical data offer promising in vivo results pointing to a potential therapeutic benefit of TLR7 and TLR9 antagonists in restenosis and accelerated atherosclerosis.”

“In addition to evaluating antagonists of TLR7 and TLR9 in autoimmune diseases, we have been conducting studies of these candidates in preclinical models of cardiovascular diseases. This presentation expands upon our prior studies, in which our TLR7 and TLR9 antagonist candidates suppressed total cholesterol in hyperlipidemic mice, as presented at AHA 2010,” said Nicola La Monica, Vice President of Biology at Idera Pharmaceuticals. “Idera’s TLR7 and TLR9 antagonist candidates have been created through a chemistry-based approach and our lead candidate, IMO-3100, is in clinical development for autoimmune diseases.”

In the present study, TLR7 and TLR9 expression was detected in femoral arteries after surgical intervention, suggesting activation by cellular stress. Formation of neointima after femoral artery cuff placement in hypercholesterolemic APOE*3Leiden mice also was observed. Neointima is a new, thickened inner layer of veins or arteries, commonly formed in patients with atherosclerosis and restenosis after balloon angioplasty. Administration of Idera’s TLR7 and TLR9 dual antagonist led to significant reduction in the formation of neointima, in signs of inflammation, and in induction of IL-10 expression.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs